Yorktown Management & Research Co Inc Holds Holdings in DENTSPLY SIRONA Inc. (XRAY)

Yorktown Management & Research Co Inc maintained its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,079 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Yorktown Management & Research Co Inc’s holdings in DENTSPLY SIRONA were worth $329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of XRAY. Commonwealth Bank of Australia boosted its stake in shares of DENTSPLY SIRONA by 19.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares during the last quarter. Dupont Capital Management Corp purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $116,000. Korea Investment CORP boosted its stake in shares of DENTSPLY SIRONA by 139.9% in the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 1,251 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $162,000. Finally, Penserra Capital Management LLC boosted its stake in shares of DENTSPLY SIRONA by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,760 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 240 shares during the last quarter. 93.97% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Inc. (NASDAQ XRAY) traded up 2.10% during trading on Friday, reaching $59.34. The company had a trading volume of 2,670,746 shares. DENTSPLY SIRONA Inc. has a 12-month low of $52.54 and a 12-month high of $65.68. The firm’s 50 day moving average price is $57.21 and its 200 day moving average price is $61.78. The firm’s market capitalization is $13.62 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company had revenue of $992.70 million for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the company posted $0.76 earnings per share. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that DENTSPLY SIRONA Inc. will post $2.68 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 29th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 0.59%. The ex-dividend date is Thursday, September 28th. DENTSPLY SIRONA’s dividend payout ratio is currently -10.09%.

WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/09/16/yorktown-management-research-co-inc-holds-holdings-in-dentsply-sirona-inc-xray.html.

A number of brokerages have recently weighed in on XRAY. Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. HC Wainwright restated a “buy” rating and issued a $68.00 target price (down previously from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. Morgan Stanley boosted their target price on DENTSPLY SIRONA from $66.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $72.00 target price on the stock in a research note on Thursday, July 13th. Finally, TheStreet downgraded DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $65.73.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply